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The histopathological features of thyroid cancers can be used to risk stratify patients, 
allowing prognostication and treatment decisions. Detailed accurate histological 
assessment by experienced pathologists working within a multidisciplinary context is 
crucial. Experience is also essential for interpretation of pre-operative thyroid 
cytology specimens, which can be challenging. There is now more international 
harmonisation of numerical reporting systems for thyroid cytology.  Understanding of 
the molecular basis of thyroid cancer has increased dramatically in recent years.  
Pre-operative molecular pathology testing, when available, can refine cytological 
diagnosis to rule in or out for surgery, as well as assisting prognostication and 
enabling targeted treatment for thyroid tumours. 
 






The most important aspect of thyroid cancer pathology is making a correct and 
timely diagnosis with provision of sufficient detailed histological information upon 
which to risk stratify patients for treatment decisions. Some aspects of thyroid 
pathology are, however, quite subjective and so there is often variation in 
pathological interpretation even between experienced endocrine pathologists. 
Recent important developments in thyroid cancer pathology include refinement of 
some prognostic features for assigning risk, a better understanding of the molecular 
basis of thyroid cancer and reclassification of one of the lowest risk tumours as non-





Increasing incidence of thyroid cancer. The incidence of thyroid cancer has 
increased in developed countries, but the mortality has remained unaltered. The rise 
is primarily due to increased use of thyroid ultrasound(1) and most of the increase is 
due to lower risk tumour types.(2)  
 
Tumour categorisation and risk. Traditionally, primary thyroid cancer was classified 
into either follicular epithelial cell derived tumours: papillary carcinoma, follicular 
carcinoma (minimally or widely invasive), and anaplastic carcinoma, with 
progressively worse prognosis; or C-cell derived medullary thyroid carcinoma 
(familial and sporadic), lymphoma and other rarer tumour types. Poorly differentiated 
thyroid carcinoma (PDC) is now recognised as an intermediate risk cancer between 
differentiated thyroid carcinoma (follicular and papillary) and anaplastic thyroid 
carcinoma (ATC). 
 
For thyroid carcinomas, precise tumour typing, as well as accurate TNM staging and 
assessment of other prognostic features, is crucial in determining the patient’s risk 
group and therefore the appropriate treatment. Histopathology reports need to be 
accurate and complete with all the relevant diagnostic and prognostic features; this is 
aided by proforma reporting using datasets or templates of the type issued by the UK 
Royal College of Pathologists (RCPath)(3) or by The College of American 
Pathologists (CAP)(4).  
 
Papillary thyroid carcinoma (PTC) subtypes.   There are many subtypes of PTC but 
perhaps the most confusing are papillary microcarcinomas and the “follicular” variant 
of papillary thyroid carcinoma (FVPTC).  
 
Papillary microcarcinomas are tumours up to 10mm in greatest dimension.  These 
may be the diagnostically targeted lesion or, more commonly, found incidentally 
either on ultrasound or histology.  Various additional histological factors enable 
assessment of their risk level, and personalised decision making may be required.(5)  
 
PTC is diagnosed primarily by its nuclear features, and may show either a papillary 
(classical) or follicular architecture, or a mixture of both.  FVPTCs show an almost 
exclusively follicular architecture, and are classified into subtypes including infiltrative 
(non-encapsulated) with molecular genetics and behaviour similar to classical PTC, 
and encapsulated (eFVPTC) where the molecular genetics and behaviour are more 
akin to follicular neoplasms.(6)  The distinction of eFVPTC from follicular thyroid 
carcinoma (FTC) therefore hinges on whether the nuclei show PTC-type nuclear 
features or not, which is notoriously subjective even among experienced endocrine 
pathologists.(7). The diagnosis of FTC has also evolved with time. In a very recent 
study, a group of American pathologists reviewed a series of 66 thyroid tumours 
originally diagnosed in 1965-2007 as FTC.  47 (71%) cases were reclassified: 24 
(36%) to PTC, 18 (27%) to follicular adenoma (FA), and 5 (8%) to PDC.  Nine of 23 
(39%) cases from 2000-2007 were reclassified as benign (FA).(8)  
 
Poorer prognostic variants of PTC include tall cell, columnar cell and diffuse 
sclerosing types, and any foci of such change needs documentation.(3,9) 
 
NIFTP  An international consensus group of pathologists led by Prof Yuri Nikiforov, 
University of Pittsburgh, reviewed 109 cases of non-invasive eFVPTC followed up for 
10 to 26 years (median 13 years). Using consensus pathological criteria, this study 
showed these tumours have a very good prognosis with less than 1% risk of death or 
recurrent disease on long-term follow-up, implying that that this tumour should be 
regarded as of very low malignant potential.   In 2016, these lesions were re-
designated “NIFTP”, non-invasive follicular thyroid neoplasm with papillary-like 
nuclear features.(10)  Diagnosis of NIFTP requires application of strict pathological 
criteria including examination of the entire tumour capsule, confirmation of the nuclei 
according to the NIFTP nuclear scoring system, absence of psammoma bodies, and 
no capsular or vascular invasion. If these criteria are not met, is not possible to make 
a diagnosis of NIFTP and the default diagnosis remains eFVPTC.  NIFTPs are 
follicular-derived tumours, they are RAS-driven lesions and they do not show 
evidence of BRAF V600E mutations.(10) The UK RCPath has produced an 
addendum to the 2014 Dataset For Thyroid Cancer Histopathology Reports detailing 
the diagnosis of NIFTP.(11) This could have a major impact, because in some 
centres up to 20% of newly diagnosed thyroid cancers are non-invasive 
eFVPTC.(12)  
 
Minimally Invasive FTC.  These are single encapsulated nodules of tumour with a 
follicular architecture but the cells lack the nuclear features of PTC.  Carcinoma is 
diagnosed when there is invasive growth, either through the tumour capsule 
(capsular invasion)(13) or within the blood vessels of the tumour capsule or adjacent 
thyroid tissue (vascular or angioinvasion),(13,14) both of which can be subjective 
histologically.(7) Vascular invasion carries higher risk than capsular invasion, so 
there should be thorough examination of the tumour capsule histologically and the 
type of invasion present should always be clearly stated.  Precise criteria for vascular 
invasion in the literature are also conflicting (4,14). Minimally invasive FTC with 
capsular invasion only and no other adverse risk factors has a very low risk of 
recurrence or metastasis and may not require completion thyroidectomy.(15-17) 
Frequent vascular invasion is an adverse prognostic feature and should be 
commented upon, with the 2016 CAP Protocol requiring distinction between focal 
(less than 4 vessels) vs extensive (4 or more vessels) whereas the 2014 UK RCPath 
Dataset does not.(4) 
PDC.   These uncommon tumours have an intermediate prognosis between 
PTC/FTC and ATC.  A previous term was “insular carcinoma”, but not all PDC have 
an insular architecture.  Diagnosis is aided by the Turin consensus criteria.(18,19) 
Diagnosis requires a follicular cell derived tumour with a solid/insular/trabecular 
growth pattern, lacking the nuclear features of PTC, and with necrosis and/or a 
mitotic count of three or more per 10 high-power fields.   The entire tumour should be 
designated as PDC if more than 50% of the tumour shows this appearance, but even 
a minority component of PDC in an otherwise well differentiated tumour should also 
be mentioned in the pathology report because this may worsen the patient’s 
prognosis.(20) 
 
Other newly described pathological entities.  These are extremely rare and are well 
reviewed by Eloy.(21) They include meningioma-like tumour of the thyroid, 
glomeruloid variant of FTC, angiomatoid PTC, hobnail/micropapillary variant of PTC.  
small cell primary non-neuroendocrine thyroid carcinoma, other primary thyroid 
tumours with Ewing-like elements, the very rare small cell neuroendocrine carcinoma 
of the thyroid, and other very rare primary thyroid neuroendocrine tumours which are 
calcitonin-negative and resemble well differentiated neuroendocrine tumours seen at 
other sites.   
 
Staging.  Worthy of discussion in an oncology review are some very simple points 
around staging. The use of extrathyroidal extension (ETE) in TNM assumes that the 
thyroid has a capsule but anatomically the thyroid has no capsule.(22)  Assessment 
of ETE therefore has poor interobserver agreement.(23)  ETE has been described as 
macroscopic vs microscopic, the former having a worse prognosis; “minimal” ETE 
(pT3) does not affect relapse-free survival.(24) 
 
Metastases to lymph nodes are frequently seen with PTC but quite rarely with FTC.  
There is evidence that the size of lymph node deposits, the ratio of involved to non-
involved lymph nodes, and extranodal extension have prognostic importance.(4,25-
28) 
 
Thyroid cytology.  Thyroid FNA cytology is the principal means of pre-operative 
diagnosis of thyroid nodules.  Numerical categorisation facilitates communication 
and audit, but does not replace the text of the report.  In the UK, The RCPath 
updated The Guidelines for Reporting Thyroid Cytology in January 2016.(29)  Many 
countries have similar numerical systems including The Bethesda System (TBS) and 
these now align well with one another, enabling comparison of the international 
literature.(29)  There is interobserver variation in interpretation of thyroid cytology, 
and central review of cytology increases accuracy, especially in the atypical 
categories.(30)   
 
Cytology can yield a definite diagnosis of thyroid cancer, permitting therapeutic 
surgery, or a non-neoplastic/benign diagnosis, permitting reassurance. There is a 
continuing problem with the indeterminate or “grey zone” cytology categories, which 
require either follow-up or diagnostic hemithyroidectomy for a histological diagnosis, 
but these are to some extent unavoidable due to the overlap of cytomorphological 
features and the need for histology to distinguish benign from malignant follicular 
neoplasms.(31) The new diagnostic entity NIFTP usually yields indeterminate 
cytology but can produce cytology that is reported as diagnostic of PTC (Thy5/TBS 
Class VI).  Clinicians need to be aware of this and exercise caution, taking into 
consideration the ultrasound appearances as well as the cytology findings.(11)  
Molecular testing for BRAF V600E mutations may also be helpful as presence of 
BRAF V600E mutation excludes a diagnosis of NIFTP in an otherwise malignant 
Thy5/TBS Class VI cytology. 
 
Molecular genetics of thyroid cancer.  Understanding of the genetic basis of thyroid 
cancer is developing rapidly, and has important diagnostic, prognostic and 
therapeutic implications.  Many different mutations and gene rearrangements can be 
seen in thyroid cancers but classical/high risk variant PTCs are predominantly driven 
by mutations of BRAF-V600E, and follicular tumours, including eFVPTC and NIFTP, 
predominantly by RAS mutations, as shown in the 2014 Thyroid Cancer Genome 
Atlas.(32)  MTCs show RET gene mutations, either sporadic or familial.  ATCs also 
show molecular phenotypes with a higher percentage of unfavourable gene 
mutations.  
 
As a “rule-in” test, the best single test is BRAF V600E; this mutation is not seen in 
benign thyroid nodules and is therefore almost 100% specific for PTC (unless the 
thyroid tumour nodule is a metastasis) but has low sensitivity because only around 
50% of PTCs have the mutation.(33)  Other gene abnormalities such as RET/PTC 
mutations or PAX8/PPAR gamma translocations are also fairly specific for malignant 
thyroid nodules but not exclusively so.  In 2015, The American Thyroid Association 
produced a statement on using molecular profiling for thyroid nodules, making the 
important point that the diagnostic value depends on the relative risk of malignancy 
in the cohort.  Therefore, a molecular test applied to lower risk thyroid cytology (eg. 
UK Thy3a/TBS Class III), if positive for gene mutation(s) in the absence of a BRAF 
V600E mutation, would have a different significance compared to the same 
mutation(s) identified in a Thy4/TBS Class V FNA.(34)  
 
A “rule-out” test, to reliably identify nodules as benign on FNA cytology, is more 
difficult.  There are several competing commercial systems available but none are 
currently available in the UK.  The system that is most widely known is the Afirma 
Veracyte system which is a proprietary micro-RNA based test.(36)  A nodule 
classified as “benign” has a risk of malignancy of about 5%, but a “suspicious” result 
with Afirma has comparatively low specificity for cancer.(33)   
 
The Thyroseq 2 system, developed by Nikiforov and colleagues in Pittsburgh, 
USA,(36-38) uses a series of known thyroid cancer gene mutations on a 
commercially available Next Generation Sequencing (NGS) platform to target known 
gene mutations present in malignant thyroid nodules. This is highly effective as both 
a “rule-in” and a “rule-out” test, although as a “rule-in” test it is not totally specific 
because some of the mutations present in malignant thyroid nodules are also seen in 
benign nodules, specifically RAS gene mutations.(33) 
 
BRAF V600E mutations are also targeted by tyrosine kinase inhibitors (TKIs), 
although there is no evidence that BRAF V600E testing is predictive of response to 
some of the newer TKIs.  Targetable mutations have also been identifed in ATC and 




Accurate pathology by experienced pathologists is crucial to the diagnosis and risk 
stratification of thyroid cancer. The future will no doubt include more widespread 
molecular testing for the diagnosis of thyroid nodules, and for targeting therapies to 
specific action gene mutations in radio-iodine refractory thyroid cancer and also the 
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